Centers | ||
|
|
|
FDA Oncology Center of Excellence Project Catalyst | EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Royal Society of Chemistry
Led by Hiroaki Suga (University of Tokyo), RSC Chemical Biology is a gold open access journal, dedicated to publishing exceptionally significant and breakthrough findings of interest to the chemical biology... View all Janssen Pharmaceuticals and Johns Hopkins To Develop New Therapies to Treat Neurological DiseasesJanssen Pharmaceuticals (Formerly OMJPI) a Johnson and Johnson entity has entered into collaboration agreement with Johns Hopkins Brain Science Institute ("BSi") at Johns Hopkins University. Janssen will be working with Johns Hopkins researchers... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
